A method for screening an antimicrobial agent which is capable of controlling microorganisms causing offensive odor in an air-conditioning system and a method for removing offensive odor in an air-conditioning system are provided. The method for screening an antimicrobial agent and the method for removing offensive odor in an air-conditioning system may be used for various purposes of industrial application. For example, they may be used to develop a novel antimicrobial agent capable of inhibiting the growth of the microorganisms or to develop an air freshener for removing offensive odor by elucidating the chemical properties of the metabolites of the microorganisms. In addition, they may be used to fundamentally remove the cause of offensive odor by providing an air-conditioning system with an environment where the microorganisms may not live.

The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

This disclosure provides a synthesized version of S. felis C4 antimicrobial peptide as a topical antibiotic. S. felis C4 can be used as a probiotic strain of skin bacteria that can be transplanted onto the diseased skin of dogs, cats and dairy cows to outcompete and kill pathogenic bacteria that are causing infections such as bacterial pyoderma and mastitis.

A method of preparing a tobacco material for use in a smokeless tobacco product is provided, the method including receiving a tobacco material, wherein the tobacco material has not been subjected to a fermentation process, blending the tobacco material with the final moist snuff product ingredients to form a tobacco composition having a moisture content of at least about 50%, packaging the tobacco composition in a final product packaging such that after a fermentation period of 7 to 28 days within the final product packaging the product is ready for direct sale and consumption.

Compositions contain at least one Staphylococcus carnosus strain, for example at least one of S. carnosus CNCM I-5398 or S. carnosus CNCM I-5400. A unit dosage form of the composition contains a prophylactically or therapeutically effective amount of the at least one Staphylococcus carnosus strain. Methods of making such compositions include adding at least one Staphylococcus carnosus strain to at least one other food component. Methods of using such compositions therapeutically or prophylactically include promoting mucosal healing; regulation of gut microbiota dysbiosis; and treatment or prevention of gut inflammatory diseases such as IBD, irritable bowel syndrome, liver inflammation (NASH,NAFLD, alcohol-induced liver injury), allergy, atopy, bone inflammation, rheumatoid arthritis, systemic lupus, Gougerot-Sjogren's syndrome, Reiter's syndrome, poliomyelitis, dermato-myositis, thyroiditis, Basedow, Hashimoto, type I diabetes, Addison's disease, auto-immunes hepatitis, celiac disease, Biermer's disease, multiple sclerosis, myasthenia, eye inflammation, obesity-associated inflammation, age-related low-grade inflammation, Blau's syndrome, Alzheimer's disease, cardiovascular diseases, atherosclerosis, metabolic syndrome, type II diabetes, gingivitis, paronditis, and food sensitivities.

A method of treating a biofilm on a surface, comprising: providing a surface having a biofilm; and administering to the surface a treatment that reduces a concentration of pyruvate of the biofilm, comprising pyruvate produced by at least a portion the biofilm, under conditions effective reducing maintenance of the biofilm on the surface. A composition, comprising purified enzyme, within a particle, effective for reducing pyruvate concentration in an aqueous suspension of the composition.

A method of inducing death or inhibiting growth or reproduction of a Gram-positive bacterial cell involves contacting the bacterial cell with a coproporphyrinogen oxidase (CgoX) activator, thereby promoting accumulation of coproporphyrin III (CPIII) in the bacterial cell, where the CPIII serves as an intracellular photosensitizer; contacting the bacterial cell with a photosensitizer conjugated to an iron-regulated surface determinant (Isd) protein targeting moiety, which Isd proteins are expressed on the service of the bacterial cell such that the conjugated photosensitizer serves as an extracellular photo sensitizer; exposing the bacterial cell to light having a first excitation wavelength of the intracellular photo sensitizer; and exposing the bacterial cell to light having a second excitation wavelength of the extracellular photosensitizer.

The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

The present invention is related to the field of reddening of food products. In particular the present invention relates to the preservation or optimization of nitrate reductase activity of frozen and/or dried lactic acid bacteria cultures or Micrococcaceae cultures (particularly cultures comprising one or more species of Staphylococcus having nitrate reductase activity).

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.